20/20 Biolabs Inc(AIDX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
October 7 at 4:04 PM ET (Korea 10/8 05:04)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.72 | Insider Own | 33.61% | Shs Outstand | 12.3M | Perf Week | -21.31% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 26.92% | Insider Trans | - | Shs Float | 8.5M | Perf Month | -40.56% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.14 | Inst Own | 4.23% | Short Float | 0.55% | Perf Quarter | -41.08% |
| Income | -0.01B | P/S | 2.15 | EPS this Y | 31.58% | Inst Trans | 3.63% | Short Ratio | 0.51 | Perf Half Y | -82.06% |
| Sales | 0.00B | P/B | 2.6 | EPS next 5Y | 14.8% | ROA | - | Short Interest | 0.05M | Perf YTD | -99.31% |
| Book/sh | 0.13 | P/C | 0.96 | EPS past 3/5Y | - 3.6% | ROE | - | 52W High | -99.31% ($50.00) | Perf Year | - |
| Cash/sh | 0.36 | P/FCF | - | Sales past 3/5Y | -43.03% -2.58% | ROIC | -164.3% | 52W Low | 3.78% ($0.33) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -257.17% | Gross Margin | 31.52% | Volatility(W/M) | 13.99% 11.54% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.95 | Sales Y/Y TTM | - | Oper. Margin | -215.69% | ATR (14) | 0.05 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.95 | EPS Q/Q | -206.97% | Profit Margin | -343.43% | RSI (14) | 26.72 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.99 | Sales Q/Q | 31.91% | SMA20 | -22.2% ($0.44) | Beta | - | Target Price | $2 |
| Payout | - | Debt/Eq | 0.18 | Earnings | 2026/8/17 | SMA50 | -29.76% ($0.48) | Rel Volume | 0.82 | Prev Close | $0.35 |
| Employees | 14 | LT Debt/Eq | 0.12 | EPS/Sales Surpr. | -116.67% 14.87% | SMA200 | -76.62% ($1.45) | Avg Volume(3M) | 0.09M | Price | $0.34 |
| IPO | 2026/2/19 | Option/Short | No/Yes | Trades | 140 | Volume | 75,373 | Change | -2.54% |
🩸 20/20 BioLabs () is a US medical diagnostics company that uses AI-powered blood tests to detect cancer and chronic diseases at an early stage. Its flagship product, OneTest™, is a Multi-Cancer Early Detection (MCED) test that screens for multiple cancers from a single blood draw. It is used in public health initiatives such as firefighter cancer screening programs and is a micro-cap healthcare stock newly listed on Nasdaq in early 2026.
Over the past 1 year, on the lower side
99% below its 1-year high.
Traded about as much as usual That is 82% of its average volume.
AIDX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +31.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $215. Peers typically go for $155.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.2%.
Tap to view numbers
It ranks #131 of 143 in the industry
Based on market cap of $4M.
FAQ
What kind of company is AIDX?
AIDX belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of AIDX?
The market cap of AIDX is approximately $4M, ranking 5,698 within its sector.
What is the 52-week high and low for AIDX?
AIDX has recorded a 52-week high of $50.00 and a low of $0.33.
